FDA
-
-
-
-
-
-
-
Biogen's diranersen shows tau reduction in Alzheimer's trial
-
-
-
-
-
-
-
Stoke Therapeutics adds Clare Kahn to board of directors
-
-
-
-
-
-
-
Biogen reports positive phase 2 results for lupus skin drug
-
-
-
-
-
-
-
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
-
-
-
-
-
-
-
BIOGEN publishes study results for high-dose nusinersen in Nature Medicine
-
-
-
-
-
-
-
BIOGEN receives EU approval for high dose SPINRAZA for spinal muscular atrophy
-
-
-
-
-
-
-
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Con
-
323,009 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

